Home / Health / New Drug Prevents COVID-19 After Exposure
New Drug Prevents COVID-19 After Exposure
25 May
Summary
- Ensitrelvir effectively prevents COVID-19 post-exposure.
- The drug lowered symptomatic COVID-19 incidence by 67%.
- This drug offers hope against future coronavirus outbreaks.
A new study indicates that Ensitrelvir can be used for post-exposure prophylaxis against COVID-19, significantly reducing infection rates. The international SCORPIO-PEP trial involved 2,387 participants exposed to the virus. Results showed that Ensitrelvir lowered symptomatic COVID-19 incidence by 67% compared to a placebo group. Furthermore, the drug reduced the overall presence of SARS-CoV-2 in contacts, demonstrating a strong safety profile. This development is crucial as Ensitrelvir offers a valuable starting point for developing drugs against the betacoronavirus family, preparing for future viral emergences.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
